XML 95 R71.htm IDEA: XBRL DOCUMENT
v3.22.4

Income Taxes - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Jan. 02, 2022 | Jan. 01, 2023 | Jan. 02, 2022 | Jan. 03, 2021 | Dec. 29, 2019
Tax Credit Carryforward [Line Items] |  |  |  |  |
Effective tax rate reconciliation, net increase (decrease) in tax rate, percent |  |  | (2.50%) |  |
Deferred tax assets, tax basis increase of certain assets due to reorganization | $ 2,300 |  | $ 2,300 |  |
Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI) |  |  | $ 1,700 |  |
Tax benefits from loss on capital assets | 1.30% |  | 1.30% | 1.20% |
Income tax expense recorded related to TRAF |  |  |  | $ 400 |
TRAF effect on tax rate |  |  |  | 2.60% |
Income tax expense related to change in tax rate from TRAF |  |  |  | $ 300 |
Deferred tax asset recorded related to TRAF |  |  |  | 450 |
Deferred tax expense related to TRAF |  |  |  | $ 300 |
Effective income tax rate reconciliation, deduction |  |  |  | 1.20% |
Unrecognized tax benefits | $ 3,323 | $ 3,829 | $ 3,323 | $ 3,373 | $ 3,853
Unrecognized tax benefits, interest on income tax expense |  | 139 | 44 | 32 |
Unrecognized tax benefits, interest on income taxes accrued | 512 | $ 651 | 512 |  |
Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent |  | 9.10% |  |  |
Incremental tax costs |  | $ 3,784 | $ 1,898 | 1,783 |
Consumer Health Business |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent |  | 2.20% |  |  |
Incremental tax costs |  | $ 500 |  |  |
State and Local Jurisdiction |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Effective tax rate reconciliation, net increase (decrease) in tax rate, percent |  |  | 2.70% |  |
Deferred tax assets, net | 600 |  | $ 600 |  |
Auris Health | Purchased in-process research and development(1) |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Impairment of intangible assets, excluding goodwill | $ 900 |  |  |  |
Effective income tax rate reconciliation, nondeductible expense, impairment losses, percent | 22.40% |  |  |  |
Internal Revenue Service (IRS) |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Payment on unrecognized tax benefit liability |  |  |  | 700 |
Consumer Health |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Litigation expense |  |  | 1,600 | 3,900 |
Pharmaceutical |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Litigation expense |  | $ 100 | 600 | $ 800 |
Talc |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Effective income tax rate reconciliation, litigation settlement, percent |  |  |  | 0.235 |
Talc | Consumer Health |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Litigation expense |  |  | $ 1,600 | $ 4,000 |
Effective income tax rate reconciliation, litigation settlement, percent |  |  | 0.235 |  |
Risperdal | Consumer Health |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Litigation expense |  |  | $ 800 |  |
Effective income tax rate reconciliation, litigation settlement, percent |  |  | 0.164 |  |
Opiods |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Effective income tax rate reconciliation, litigation settlement, percent |  |  |  | 0.214 |
Opiods | Pharmaceutical |  |  |  |  |
Tax Credit Carryforward [Line Items] |  |  |  |  |
Litigation expense |  |  |  | $ 1,000 |

X
- Definition Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization + References No definition available. + Details
Name: | jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Effective Income Tax Rate Reconciliation, Capital Loss + References No definition available. + Details
Name: | jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent + References No definition available. + Details
Name: | jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent + References No definition available. + Details
Name: | jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
Namespace Prefix: | jnj_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent + References No definition available. + Details
Name: | jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent + References No definition available. + Details
Name: | jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit) + References No definition available. + Details
Name: | jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset + References No definition available. + Details
Name: | jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit) + References No definition available. + Details
Name: | jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit) + References No definition available. + Details
Name: | jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI) + References No definition available. + Details
Name: | jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Unrecognized Tax Benefit Liability, Payment + References No definition available. + Details
Name: | jnj_UnrecognizedTaxBenefitLiabilityPayment
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319 + Details
Name: | us-gaap_DeferredTaxAssetsLiabilitiesNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.4) -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817 + Details
Name: | us-gaap_EffectiveIncomeTaxRateReconciliationDeductions
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.4) -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319 + Details
Name: | us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 20 -Section 45 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794 + Details
Name: | us-gaap_IncomeTaxExpenseBenefit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_TaxCreditCarryforwardLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of unrecognized tax benefits. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 10B -URI https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319 + Details
Name: | us-gaap_UnrecognizedTaxBenefits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of interest expense accrued for an underpayment of income taxes. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319 + Details
Name: | us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of interest expense for an underpayment of income taxes. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319 + Details
Name: | us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=jnj_ConsumerHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=jnj_TalcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=jnj_RisperdalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=jnj_OpiodsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |